Global Finance News
27 Aug 2026, 16:41
Amgen and AstraZeneca Report Positive Phase 3 TEZSPIRE Results in Eosinophilic Esophagitis
Amgen (NASDAQ: AMGN) and AstraZeneca reported positive Phase 3 results for TEZSPIRE in patients with eosinophilic esophagitis (EoE), potentially opening another major indication for the drug.
In the CROSSING trial, TEZSPIRE achieved statistically significant and clinically meaningful improvements across both co-primary endpoints — histologic remission and the frequency and severity of difficulty swallowing — at Week 24. The benefits were sustained through Week 52, while the safety profile remained generally consistent with TEZSPIRE’s currently approved indications.
The Phase 3 trial enrolled 368 adults and adolescents with symptomatic, active EoE and compared two TEZSPIRE doses with placebo. Full results will be presented at an upcoming medical meeting and submitted to regulatory authorities.
The results are strategically important because EoE would represent a third epithelial-driven inflammatory disease in which TEZSPIRE has demonstrated efficacy. The drug is already approved for severe asthma and inadequately controlled chronic rhinosinusitis with nasal polyps in several major markets.
Amgen (NASDAQ: AMGN) and AstraZeneca reported positive Phase 3 results for TEZSPIRE in patients with eosinophilic esophagitis (EoE), potentially opening another major indication for the drug.
In the CROSSING trial, TEZSPIRE achieved statistically significant and clinically meaningful improvements across both co-primary endpoints — histologic remission and the frequency and severity of difficulty swallowing — at Week 24. The benefits were sustained through Week 52, while the safety profile remained generally consistent with TEZSPIRE’s currently approved indications.
The Phase 3 trial enrolled 368 adults and adolescents with symptomatic, active EoE and compared two TEZSPIRE doses with placebo. Full results will be presented at an upcoming medical meeting and submitted to regulatory authorities.
The results are strategically important because EoE would represent a third epithelial-driven inflammatory disease in which TEZSPIRE has demonstrated efficacy. The drug is already approved for severe asthma and inadequately controlled chronic rhinosinusitis with nasal polyps in several major markets.
